Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shaperon Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 5 distinct examiners and 4 distinct art units, indicating some overlap in assignments. A centralized docket process can help identify shared prosecution issues while preserving separate examiner strategies.
MOORE, SUSANNA is the busiest examiner, with 2 pending matters. That assignment is the portfolio’s stated concentration point, while the remaining matters require attention across the other examiner channels.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 2 | 68.0% | +31.6% |
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
| CHAO, ALLEN | 1 | 60.0% | +0.0% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | MOORE, SUSANNA | 6d |
| 18906683 | COMPOSITION FOR PREVENTING OR TREATING PULMONARY FIBROSIS, COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | ARCORIA, PAUL JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | MOORE, SUSANNA | 6d |
| 18708357 | COMPOSITION CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES | MOORE, SUSANNA | — |
| 18694190 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS | RODRIGUEZ-GARCIA, VALERIE | — |
| 18277931 | BISPECIFIC SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47 AND USE THEREOF | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1624 | 2 |
| 1622 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18906683 | COMPOSITION FOR PREVENTING OR TREATING PULMONARY FIBROSIS, COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | ARCORIA, PAUL JOSEPH | 1621 | §103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18561881 | COMPOSITION FOR TREATMENT OF COVID-19 COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | CHAO, ALLEN | 1622 | §103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18708357 | COMPOSITION CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES | MOORE, SUSANNA | 1624 | §102§112DP | Non-Final OA | — | Pending | May 08, 2024 |
| 18694190 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS | RODRIGUEZ-GARCIA, VALERIE | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18277931 | BISPECIFIC SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47 AND USE THEREOF | HADDAD, MAHER M | 1641 | §102§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | MOORE, SUSANNA | 1624 | §103§112 | Final Rejection | 6d | Pending | Mar 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShaperon Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Susanna Moore has the most, with 2 of Shaperon Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
